TG Therapeutics: The Cloud Over Briumvi (NASDAQ:TGTX)

6 mins read

Today, we take a look at TG Therapeutics (NASDAQ:TGTX) for the first time in years. The shares of this B-cell therapy concern are down some 60% from their 52-week high after rival multiple sclerosis therapy Ocrevus achieved non-inferiority

Read the full article here

Leave a Reply

Your email address will not be published.

Previous Story

Hear Trump’s remark outside court that made an ex-prosecutor’s ears perk up

Next Story

Book bans are accelerating across the country amid right-wing pressure campaign

Latest from News